Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial
暂无分享,去创建一个
R. Holman | C. Antoniades | L. Valkovič | J. Griffin | O. Rider | E. Wicks | H. Lamlum | C. Rodgers | M. Mahmod | B. Raman | R. Coleman | D. Massey | Jisoo Lee | F. Mózes | A. Adler | M. Hundertmark | J. Milton | A. Nazeer | S. Monga | S. Neubauer | J. Miller
[1] D. Kass,et al. Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction , 2023, Circulation.
[2] R. Holman,et al. Empagliflozin in acute myocardial infarction: the EMMY trial , 2022, European heart journal.
[3] Chi‐Hang Lee,et al. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiac Imaging Parameters: A Systematic Review and Meta-analysis of Randomized Controlled Trials , 2022, Journal of cardiovascular imaging.
[4] Svati H Shah,et al. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF , 2022, Circulation.
[5] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.
[6] G. Sinagra,et al. [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.
[7] S. Neubauer,et al. Energetic Basis for Exercise-Induced Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction , 2021, Circulation.
[8] P. Kellman,et al. Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes , 2021, Diabetes.
[9] R. Tian,et al. Cardiac Energy Metabolism in Heart Failure , 2021, Circulation research.
[10] R. Holman,et al. Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure , 2021, ESC heart failure.
[11] S. Rapacchi,et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study , 2021, Cardiovascular Diabetology.
[12] E. Ferrannini,et al. Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlled, exploratory study , 2021, Diabetes, obesity & metabolism.
[13] P. Ponikowski,et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial , 2021, European heart journal.
[14] G. Fonarow,et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2021, Journal of the American College of Cardiology.
[15] Deepak L. Bhatt,et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.
[16] Yu Liang,et al. Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF , 2020, Circulation research.
[17] J. Rabinowitz,et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart , 2020, Science.
[18] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[19] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[20] M. Su,et al. Myocardial adipose deposition and the development of heart failure with preserved ejection fraction , 2019, European journal of heart failure.
[21] R. Nishimura,et al. Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial , 2019, Advances in Therapy.
[22] M. Drazner,et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. , 2019, Circulation.
[23] R. D. de Boer,et al. Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction , 2019, European journal of heart failure.
[24] J. Reagan,et al. Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction , 2019, JACC. Basic to translational science.
[25] H. Bøtker,et al. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients , 2019, Circulation.
[26] D. Abdurrachim,et al. Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13C magnetic resonance spectroscopy study , 2018, Diabetes, obesity & metabolism.
[27] K. Nicolay,et al. Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice , 2018, Cardiovascular research.
[28] S. Verma,et al. Empagliflozin Increases Cardiac Energy Production in Diabetes , 2018, JACC. Basic to translational science.
[29] V. Fuster,et al. EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY , 2018 .
[30] M. Hlatky,et al. Innovation in Heart Failure Treatment: Life Expectancy, Disability, and Health Disparities. , 2018, JACC. Heart failure.
[31] P. Kellman,et al. Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis , 2018, Journal of the American College of Cardiology.
[32] Matthew D Robson,et al. OXSA: An open-source magnetic resonance spectroscopy analysis toolbox in MATLAB , 2017, PloS one.
[33] S. Verma,et al. Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure , 2017, JACC. Basic to translational science.
[34] M. Young,et al. Metabolic Origins of Heart Failure , 2017, JACC. Basic to translational science.
[35] I. Buchan,et al. Do patients have worse outcomes in heart failure than in cancer? A primary care‐based cohort study with 10‐year follow‐up in Scotland , 2017, European journal of heart failure.
[36] E. Ferrannini,et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis , 2016, Diabetes Care.
[37] Rick B. Vega,et al. The Failing Heart Relies on Ketone Bodies as a Fuel , 2016, Circulation.
[38] B. Zinman,et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.
[39] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[40] E. Ferrannini,et al. Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.
[41] M. Kuehl,et al. Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. , 2015, JACC. Heart failure.
[42] T. Heise,et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.
[43] Luigi Atzori,et al. Metabolomics as a tool for cardiac research , 2011, Nature Reviews Cardiology.
[44] A. Henning,et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. , 2009, Journal of the American College of Cardiology.
[45] M. Robson,et al. Reproducibility of 31P cardiac magnetic resonance spectroscopy at 3 T , 2009, NMR in biomedicine.
[46] Joachim Selbig,et al. pcaMethods - a bioconductor package providing PCA methods for incomplete data , 2007, Bioinform..
[47] Stefan Neubauer,et al. The creatine kinase energy transport system in the failing mouse heart. , 2006, Journal of molecular and cellular cardiology.
[48] Frederick P Roth,et al. Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia , 2005, Circulation.
[49] Robert G Weiss,et al. Is the failing heart energy starved? On using chemical energy to support cardiac function. , 2004, Circulation research.
[50] M. D'Andrea,et al. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1) , 2003, Journal of cellular biochemistry.
[51] S. Vatner,et al. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. , 1999, Circulation.
[52] R. Starling,et al. Human myocardial ATP content and in vivo contractile function , 1998, Molecular and Cellular Biochemistry.
[53] S. Neubauer,et al. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. , 1995, European heart journal.
[54] S. Neubauer,et al. 31P Magnetic Resonance Spectroscopy in Dilated Cardiomyopathy and Coronary Artery Disease: Altered Cardiac High‐Energy Phosphate Metabolism in Heart Failure , 1992, Circulation.
[55] G. Radda,et al. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy , 1991, The Lancet.